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Abstract
Rationale: One in 12 adults has chronic obstructive pulmonary disease or
asthma. Acute exacerbations of these chronic lower respiratory diseases
(CLRDs) are a major cause of morbidity and mortality. Valid approaches to
classifying cases and exacerbations in the general population are needed to
facilitate prevention research.
Objectives: To assess the feasibility, reproducibility, and performance of a
protocol to identify CLRD cases and exacerbations triggering emergency
department (ED) visits or hospitalizations in cohorts of patients derived from
general populations of adults.
Methods: A protocol was developed to classify CLRD cases and severe
exacerbations on the basis of review of medical records. ED and inpatient
medical records were ascertained prospectively in the Hispanic Community
Health Study/Study of Latinos, and inpatient records were retrospectively
identified by administrative codes in the Multi-Ethnic Study of
Atherosclerosis. “Probable” exacerbations were defined as a physician’s
diagnosis of CLRD with acute respiratory symptoms. “Highly probable”
exacerbations additionally required systemic corticosteroid therapy, and
“definite” exacerbations required airflow limitation or evidence of CLRD on
imaging studies. Adjudicated results were compared with CLRD cases
identified by spirometry and self-report, and with an administrative
definition of exacerbations.
Measurements and Main Results: Protocol-based classification was
completed independently by two physicians for 216 medical records (56 ED
visits and 61 hospitalizations in the Hispanic Community Health Study/
Study of Latinos; 99 hospitalizations in the Multi-Ethnic Study of
Atherosclerosis). Reviewer disagreement occurred in 2–5%of cases and 4–8%
of exacerbations. Eighty-nine percent of records were confirmed as at least
probable CLRD cases. Fifty-six percent of confirmed CLRD cases had airflow
limitation on the basis of baseline study spirometry. Of records that described
CLRD as the primary discharge diagnosis code, an acute exacerbation was
confirmed as at least probable for 96% and as highly probable or definite for
77%. Only 50% of records with CLRD as a secondary code were confirmed,
although such records accounted for over half of all confirmed exacerbations.
Conclusions: CLRD cases and severe exacerbations without preceding
documentation of airflow limitation are identified frequently in population-
based cohorts of persons. A primary discharge diagnosis of CLRD is specific
but insensitive for defining exacerbations. Protocol-based classification of
medical records may be appropriate to supplement and to validate
identification of CLRD cases and exacerbations in general population studies.
Clinical trials registered with www.clinicaltrials.gov (NCT00005487 and
NCT02060344).
Keywords: administrative data, asthma, chronic obstructive pulmonary
disease, disease progression, incidence.
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Chronic lower respiratory disease (CLRD),
which affects approximately 1 in 12 people
worldwide, is the third leading cause of
death (1). As defined by the CDC and
the World Health Organization, CLRD
encompasses four frequently overlapping
chronic lung diseases: chronic obstructive
pulmonary disease (COPD), chronic
bronchitis, emphysema, and asthma (2–4).
The major cause of CLRD morbidity and
mortality is CLRD exacerbations, or
episodic worsening of respiratory
symptoms (5). Severe CLRD exacerbations,
which require an emergency department
(ED) visit or hospitalization, account for
more than 50% of CLRD costs (6).
Population-based research in
epidemiologic cohort studies and
administrative databases such as electronic
health records is essential to informing
primary prevention of CLRD, a current
priority of the National Heart, Lung, and
Blood Institute. However, standard
approaches to identifying and classifying
CLRD cases and CLRD exacerbations in
cohort studies or administrative databases
are lacking. Spirometric definitions of
COPD may be insufficient to detect persons
at risk of CLRD exacerbations and CLRD-
related mortality (6–13), and the validity
of administrative definitions for CLRD
exacerbations remains uncertain (14–16).
Central physician adjudication of medical
records for major adverse cardiac events
is a routine approach to minimizing bias
in cardiovascular cohort studies and
randomized clinical trials (17, 18), and yet
no similar standard has been applied to
CLRD events, even in major randomized
clinical trials (19–22).
We therefore developed a protocol for
ascertainment and physician adjudication of
CLRD cases and CLRD exacerbations in the
Hispanic Community Health Study/Study
of Latinos (HCHS/SOL) and further
evaluated it in the Multi-Ethnic Study of
Atherosclerosis (MESA). We compared
protocol-based classifications with self-report,
spirometry, and administrative definitions for
CLRD cases and CLRD exacerbations.
Preliminary results of these studies were
previously reported in abstract form (23).
Methods
Approval and Consent
The protocols and all studies described
herein were approved by the institutional
review boards of all collaborating
institutions and the National Heart, Lung,
and Blood Institute, and all participants
provided written informed consent for all
study procedures.
Ascertainment
HCHS/SOL. HCHS/SOL is a multicenter,
prospective, population-based cohort study
of Hispanic/Latino Americans that enrolled
16,415 participants 18–74 years of age who
self-identified as Hispanic or Latino in the
2008–2011 period. Study visits were
conducted in English or Spanish in San
Diego, California; Chicago, Illinois; Bronx,
New York; and Miami, Florida (24). This
analysis includes all events occurring
during the first 3 years of HCHS/SOL that
were classified before March 1, 2015.
Participants were called every
12 months to identify ED visits for CLRD
exacerbations and hospitalizations for any
cause. CLRD exacerbations not requiring
an ED visit or hospitalization were not
ascertained. All reported events were
investigated and processed through the
HCHS/SOL Events Classification
Committee.
Events were eligible for CLRD
adjudication if they were assigned an
International Classification of Diseases
(ICD) discharge diagnosis code, in any
code position, for asthma (ICD-9 code
493 and ICD-10 codes J45–J46), chronic
airway obstruction (ICD-9 code 496 and
ICD-10 code J44), emphysema (ICD-9
code 492 and ICD-10 code J43), chronic
obstructive bronchitis (ICD-9 codes
490–491 and ICD-10 codes J40–J42),
bronchiectasis (ICD-9 code 494 and ICD-
10 code J47), pulmonary heart disease
(ICD-9 codes 415 and 416.9 and ICD-10
codes I26 and I27.9), or respiratory failure
(ICD-9 code 518 and ICD-10 code J96),
or if the discharge summary included
relevant keywords (see Table E1 in the
online supplement).
For eligible events, the field center
attempted to obtain the following additional
information: physician, triage, and nurse
notes; treatments; blood count and arterial
blood gases; temperature; arterial
oxyhemoglobin saturation; chest radiology
reports; peak flow; and pulmonary function
test results. Records were blinded by the
field center before transmission to the
coordinating center for centralized
abstraction and adjudication.
MESA. MESA is a multicenter,
prospective, population-based cohort
study that enrolled 6,814 participants
45–84 years of age who were free of clinical
cardiovascular disease and self-classified
as non-Hispanic white, African American,
Hispanic, or Chinese in the 2000–2002
period (25). Participants were recruited in
Forsyth County, North Carolina; northern
Manhattan and the Bronx in New York,
New York; Baltimore, Maryland; St. Paul,
Minnesota; Chicago, Illinois; and Los
Angeles, California. This analysis includes
eligible events occurring before July 1, 2013,
of which no more than 25 were randomly
sampled from each study site.
MESA participants were called every
9 months to ascertain all hospital
admissions. Complete medical records,
including discharge diagnoses, were
requested for all hospitalizations and were
investigated and processed through the
MESA Events Classification Committee.
In the present study, we retrospectively
ascertained events eligible for CLRD
classification, which were defined as
hospitalizations assigned a primary
discharge diagnosis of a CLRD (ICD-9
codes 490–493 or 496 or ICD-10 codes
J40–J46).
Protocol
The classification protocol was developed
in 2011 in HCHS/SOL by an expert panel
of pulmonologists, allergists, pulmonary
epidemiologists, and internists, taking into
account discussions by an earlier expert
panel (see ACKNOWLEDGMENT section
before the REFERENCES). Medical records
were evaluated for (1) whether the
participant had CLRD and (2) if so,
whether the hospitalization or ED visit was
caused by CLRD exacerbation. The draft
protocol was piloted on a random subset
of MESA medical records by a single
reviewer, who recommended refinements
to improve efficiency, accuracy, and
reproducibility.
The final protocol defined CLRD cases
and CLRD exacerbations as summarized in
Table 1. (For the full protocol, see the
online supplement.) Major CLRD
subphenotypes were systematically
evaluated according to standard definitions
(3, 4, 26).
Reviewers
Reviewers included pulmonologists, allergists,
and internists trained via conferences and
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online documentation. The first 23 events in
HCHS/SOL were adjudicated by all eight
HCHS/SOL reviewers. Disagreements were
discussed, and final determinations were
achieved by consensus. The remaining
193 records were independently reviewed
by two physicians blinded to results from the
pilot phase, study data, and ICD coding.
Disagreements between reviewers for
confirmation of CLRD cases and CLRD
exacerbations triggered independent
adjudication by a third reviewer, the referee,
for 27 HCHS/SOL records and 7 MESA
records. Two reviewers and one referee were
common to both studies.
Other Measures
Study spirometry was performed at the
baseline examination (2008–2011) for all
consenting HCHS/SOL participants and in
2004–2006 for all MESA-Lung participants
(27) using the same protocol (28, 29).
Airflow limitation was defined on the basis
of prebronchodilator spirometry as a
ratio of FEV1 to FVC less than 0.70 (3).
Restriction on spirometry was defined as an
FVC percent predicted less than 80%,
calculated using Hankinson reference
equations (28) without airflow limitation.
Baseline age, sex, race and/or ethnicity,
physician-diagnosed CLRD, and tobacco
use were self-reported. Never smoking was
defined as a lifetime smoking history of less
than 100 cigarettes, and current smoking
was defined as cigarette use within the
preceding 30 days. Pack-years were
calculated as (cigarettes per day divided
by 20) multiplied by years of smoking.
Comparisons
Protocol-confirmed CLRD cases and CLRD
exacerbations were defined as those
classified as probable, highly probable, or
definite. For nonrefereed classifications, in
cases where reviewers disagreed regarding
the certainty of classification, the more
conservative decision is reported.
Protocol classifications at two levels of
certainty—“at least probable” and “highly
probable or definite”—were compared with
two alternative CLRD case definitions
(airflow limitation on study spirometry and
self-reported CLRD) and, in HCHS/SOL,
with an administrative definition of CLRD
exacerbations as hospitalization or ED visit
with CLRD as the primary discharge
diagnosis. Sensitivity, specificity, positive
predictive value (PPV) and negative
predictive value (NPV) were calculated
using the protocol classification as the
reference standard.
Statistical Analysis
The characteristics of events eligible for and
undergoing classification were evaluated
and compared using x2 and Student’s
t tests. Interrater agreement was assessed
Table 1. Classification of chronic lower respiratory disease cases and severe chronic
lower respiratory disease exacerbations
Classification Criteria
CLRD case (subphenotypes*)
Probable Physician documentation in the medical record of at least
one of the following:
d Past medical history or new diagnosis of COPD,
emphysema, chronic bronchitis, and/or asthma (defines
probable subphenotypes).
d Outpatient prescription of inhaled long- or short-acting
anticholinergic agent, inhaled corticosteroid (excluding
intranasal administration), long-acting b-agonist,
combination inhaled long-acting b-agonist and
corticosteroid, theophylline, or roflumilast. Isolated
inhaled short-acting b-agonist therapy does not qualify.
Highly probable Confirmation of probable CLRD case, plus physician
documentation of at least one of the following
diagnostic test results, qualitatively or quantitatively,
which may have been obtained during or before the
current event:
d Spirometry showing incompletely reversible airflow
limitation (COPD).
d Chest radiography or CT demonstrating emphysema
(emphysema).
d Spirometry or PEF showing reversible airflow limitation
(asthma).
d History of bronchitis event within the past 2 yr (chronic
bronchitis)
Definite Formal diagnostic test results from the current event in
the medical record:
d Spirometry with incompletely reversible airflow
limitation, defined as post-bronchodilator FEV1/FVC
ratio ,0.70 or the LLN (COPD).
d Chest radiography or CT demonstrating emphysema
(emphysema), hyperinflation, or flattened diaphragm.
d Spirometry showing reversible airflow limitation or PEF
,70% predicted, with or without reversibility (defined
by an observed improvement in PEF >30%), or, in the
absence of repeated PEF, by a clear improvement in clinical
status (if reversible and age of onset ,45 yr, asthma).
d Clinical history of bronchitis 3 mo/yr for the past 2 yr
(chronic bronchitis).
CLRD exacerbation
Probable Confirmation of probable CLRD case, combined with at
least one of the following:
d Self-report of new onset or worsening of dyspnea,
cough, sputum, or wheeze.
d Physical examination with use of accessory muscles,
respiratory distress, wheezing, or prolonged expiration.
Highly probable Confirmation of probable CLRD exacerbation, plus
administration and/or prescription of systemic
corticosteroids.
Definite Confirmation of highly probable or definite CLRD case
and highly probable CLRD exacerbation.
Definition of abbreviations: CLRD = chronic lower respiratory disease; COPD= chronic obstructive
pulmonary disease; CT = computed tomography; LLN = lower limit of normal; PEF = peak expiratory
flow.
*Classification of CLRD subphenotypes was performed after establishment of whether and with what
certainty CLRD was present. Subphenotype correspondence is indicated in brackets. Additional
information is included in the online supplement.
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via positive agreement, negative agreement,
and the Cohen’s k-statistic (30). All
statistical analyses were performed in
SAS version 9.3 software (SAS Institute,
Cary, NC).
Results
Events
HCHS/SOL. Of 176 eligible ED visits and
hospitalizations accrued by the cutoff date,
there were no differences in event or
participant characteristics between the 117
(66%) classified events and those pending
classification (Figure 1, Tables E2 and E3).
Approximately one-third of classified ED
visits and one-fifth of hospitalizations were
assigned a primary discharge diagnosis
code for CLRD, most commonly asthma
(Table 2). The majority of participants were
women and ever smokers; 52% were
obese; and 80% had self-reported CLRD,
of whom 92% had self-reported asthma.
Approximately one-third had airflow
limitation and one-fourth had restriction
on the basis of study spirometry (Table 2).
MESA. Of 143 eligible hospitalizations,
113 were randomly sampled, of which
99 (88%) were sufficiently complete for
classification (Figure 1). There were no
differences in event or participant
characteristics between classified and
nonclassified eligible hospitalizations
(Tables E3 and E4).
All MESA hospitalizations were
assigned a primary discharge diagnosis
code for CLRD, with asthma, bronchitis,
and COPD being the most common codes
(Table 2). The majority of participants
were women and smokers, and 48% had
self-reported CLRD, of whom 67% had
self-reported asthma. Approximately
two-thirds had airflow limitation and 5%
had restriction on the basis of study
spirometry (Table 2).
Reliability
HCHS/SOL. There was excellent agreement
in ED records for classification of CLRD
cases (k = 0.88; 95% confidence interval
[CI], 0.71–1.00]) and CLRD exacerbations
(k = 0.90; 95% CI, 0.78–1.00]), with 4%
reviewer disagreement. There was also
excellent agreement in hospitalization
records for CLRD cases (k = 0.85; 95% CI,
0.69–1.00) and CLRD exacerbations
(k = 0.84; 95% CI, 0.70–0.97), with a
slightly greater frequency of disagreement
(Table 3).
MESA. Relatively low k-values—0.74
(95% CI, 0.40–1.00) and 0.42 (95% CI,
0.07–0.78) for CLRD cases and CLRD
exacerbations, respectively—were observed
76 eligible ED visits
56 ED visits classified
16,415 HCHS/SOL participants with
median 2 years of follow-up
16,313 participants without CLRD-
coded hospitalization or ED visit
Hispanic Community Health Study/Study of Latinos (HCHS/SOL) 
100 eligible hospitalizations
61 hospitalizations classified
54 pending abstraction and review
5 pending adjudication 
735 hospitalizations with CLRD as a
discharge diagnosis
143 hospitalizations with CLRD as
primary discharge diagnosis
113 medical records requested
99 events classified
6814 MESA participants with 
median 12 years of follow-up
Up to 25 hospitalizations sampled
from each MESA site
8 records missing
6 records limited to ICDs only
592 hospitalizations with CLRD as
non-primary ICD code
6426 participants without CLRD-
coded hospitalization
Multi-Ethnic Study of Atherosclerosis (MESA)
Figure 1. Classification samples for the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and the Multi-Ethnic Study of Atherosclerosis
(MESA), 2000–2013. CLRD = chronic lower respiratory disease; ED = emergency department; ICD = International Classification of Diseases.
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due to high expectation of agreement
(31, 32). Reviewers disagreed on classification
of 2% of cases and 7% of exacerbations.
Confirmation
HCHS/SOL. Eighty-two percent of HCHS/
SOL classified records were confirmed as
demonstrating at least probable CLRD
cases (Figure 2, Table E5). Cases were
subclassified mainly as asthma. Among
the 46 ED visits and 50 hospitalizations
confirmed as CLRD cases, 77% were
confirmed as at least probable CLRD
exacerbations and 56% as highly probable
or definite CLRD exacerbations.
Limiting to the analysis to records
with CLRD as the primary discharge
diagnosis, 95% of ED records were
confirmed as at least probable CLRD
exacerbations and 85% as highly probable
or definite CLRD exacerbations. All
hospitalization records with a primary
discharge diagnosis of CLRD were
confirmed as highly probable or definite
CLRD exacerbations.
MESA. Almost all (97%) classified
MESA records were confirmed as at least
probable CLRD cases (Figure 2), the
majority of which were subclassified as
COPD. Ninety-six percent of classified
MESA hospitalizations were confirmed as
at least probable CLRD exacerbations and
73% as highly probable or definite CLRD
exacerbations.
Comparison with Study Spirometry
A greater percentage of events were
confirmed as CLRD cases and CLRD
exacerbations in persons with airflow
limitation compared with those without
airflow limitation on the basis of study
spirometry (Figure 3, Table E6). However,
only 56% of probable CLRD cases occurred
in participants with airflow limitation on
the basis of study spirometry. Consistent
with these results, airflow limitation on
the basis of study spirometry showed a
high PPV for protocol-defined CLRD cases,
but NPV was low (Figure 4, Table E7).
Percentages of events confirmed as CLRD
cases and CLRD exacerbations did not
differ by the presence or absence of
restriction on the basis of spirometry
(Table E8).
Comparison with Self-reported CLRD
at Study Baseline
In persons with self-reported CLRD at
study baseline, a greater percentage of events
were confirmed as CLRD cases and CLRD
exacerbations (Figure 3, Table E6); yet,
confirmed new diagnoses of CLRD cases
and CLRD exacerbations were frequent in
both cohorts. In MESA, which had a longer
follow-up period, 41% of probable
CLRD exacerbations and 36% of highly
probable or definite CLRD exacerbations
occurred among persons without self-
reported CLRD at study baseline. Of 19%
of events occurring in both cohorts among
persons with neither airflow limitation nor
self-reported CLRD at baseline, 29% were
confirmed as CLRD exacerbations.
Comparison with an Administrative
Definition of Exacerbation
A great percentage of events assigned a
primary discharge diagnosis of CLRD were
confirmed as CLRD cases and CLRD
exacerbations (Figure 3, Table E6), whereas
half of events without a primary discharge
diagnosis of CLRD were not confirmed
as CLRD exacerbations. The PPV of
primary discharge diagnosis code for
Table 2. Baseline characteristics of participants with classified emergency department
visits or hospitalizations
HCHS/SOL MESA
ED Visits Hospitalizations Hospitalizations
Classified events, n 56 61 99
Primary discharge ICD diagnosis code
COPD (ICD-9 codes 496, 506.4; or
ICD-10 code J44)
0 0 15 (15%)
Emphysema (ICD-9 code 492 or
ICD-10 code J43)
0 0 3 (3%)
Bronchitis (ICD-9 codes 490–491 or
ICD-10 codes J40–J42)
3 (5%) 1 (2%) 40 (40%)
Asthma (ICD-9 code 493 or ICD-10
codes J45–J46)
17 (30%) 12 (20%) 41 (41%)
Any CLRD 20 (36%) 13 (21%) 99 (100%)
Participants, n 50 56 75
Age, yr 51 (13) 54 (12) 67 (8.8)
Male sex 6 (15%) 17 (34%) 29 (39%)
Body mass index, kg/m2 31 (6) 32 (9) 30 (8)
Race/ethnicity
White — — 29 (39%)
African American — — 24 (32%)
Hispanic/Latino 50 (100%) 56 (100%) 15 (20%)
Asian — — 7 (9%)
Smoking status
Never 23 (47%) 23 (43%) 19 (25%)
Former 16 (33%) 14 (26%) 31 (41%)
Current 10 (20%) 17 (32%) 25 (33%)
Pack-years of smoking 15 (15) 20.0 (17) 36.5 (26)
Self-reported CLRD
Asthma 36 (77%) 36 (68%) 36 (36%)
COPD, emphysema, or chronic
bronchitis
17 (36%) 21 (40%) 12 (16%)
Baseline spirometry
FEV1, % predicted, L 74 (25) 76 (22) 68 (32)
FEV1/FVC ratio 0.75 (0.11) 0.73 (0.12) 0.58 (0.17)
Airflow limitation 14 (35%)* 15 (30%)* 24 (65%)†
Restrictive pattern 9 (23%)* 13 (26%)* 2 (5%)†
Definition of abbreviations: CLRD = chronic lower respiratory disease; COPD= chronic obstructive
pulmonary disease; ED = emergency department; HCHS/SOL =Hispanic Community Health Study/
Study of Latinos; ICD = International Classification of Diseases; MESA =Multi-Ethnic Study of
Atherosclerosis.
Airflow limitation is defined as a prebronchodilator FEV1/FVC ratio ,0.70. A restrictive pattern is
defined as a prebronchodilator FEV1/FVC ratio >0.70 and an FVC percent predicted ,80%.
Values are presented as mean (SD) or frequency (percent), with the percentages calculated out of
participants with nonmissing data.
*In HCHS/SOL, 88 of 102 participants with classified events had valid spirometric measures.
†In MESA, 37 of 75 participants with classified events had valid spirometric measures that were
performed in 2004–2006 (approximately 4 yr after baseline examination and initiation of event follow-up).
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protocol-confirmed CLRD exacerbation
was excellent (Figure 4, Table E9).
However, the NPV was 50%, and restriction
of event ascertainment in HCHS/SOL
to the 36% of ED visits and 21% of
hospitalizations with a primary ICD code
for CLRD would have reduced the number
of confirmed CLRD exacerbations by 57%.
Subphenotypes
Reviewer agreement was similar for CLRD
subphenotypes of COPD, emphysema,
chronic bronchitis, and asthma (Table E10).
Asthma was confirmed in approximately
three-fourths of HCHS/SOL records versus
one-third of MESA records, whereas COPD
was confirmed in one-fifth of HCHS/SOL
records and two-thirds of MESA records
(Table E11). Comorbid asthma and COPD
were confirmed in 5%. In the pooled cohort
sample, the PPV of airflow limitation
was similar for asthma and COPD, whereas
the NPV of airflow limitation was greater for
COPD than for asthma (Table E12).
One-fourth of confirmed COPD cases
occurred among participants without
airflow limitation on the basis of study
spirometry.
Discussion
CLRD cases and CLRD exacerbations were
defined in two population-based cohorts
of adults in the United States by using a new
classification protocol based upon review
of medical records of ED visits and
hospitalizations. Interrater agreement was
excellent. Almost all medical records
with a primary discharge diagnosis
code for a CLRD were confirmed as
CLRD exacerbations, compared with
approximately half of those with CLRD
as a nonprimary discharge diagnosis code.
Our results suggest that the protocol is a
practical and reliable approach to defining
incident CLRD cases and exacerbations in
general population studies, which is an
important step toward valid epidemiologic
research on primary and secondary
prevention of CLRD.
We confirmed a substantial number
of CLRD cases and CLRD exacerbations
among persons without airflow limitation
on the basis of study spirometry or
self-reported disease at baseline who would
not be captured by current standard
epidemiologic definitions (33, 34). In
persons without previously documented
airflow limitation, many of the confirmed
CLRD cases were subphenotyped as
asthma, which is not defined by fixed
airflow limitation; however, persons
without airflow limitation also gave rise
to one-fourth of confirmed COPD cases.
These findings are consistent with recent
reports of the clinical importance of
respiratory exacerbations and related
events in persons without documented
baseline airflow limitation in the CanCOLD
(35), MESA (7), COPDGene (8), and
SPIROMICS (9) studies. Such events may
correspond to dynamic airflow limitation
attributable to emphysematous lung
changes or asthma–COPD overlap (2),
which were not uncommon in the present
study. Confirmed CLRD cases in persons
without baseline airflow limitation on
the basis of study spirometry may also
correspond to incident airflow limitation.
Any of these potential explanations
support consideration of incident CLRD
exacerbations as sentinel events and thus as
promising targets for primary prevention
research and interventions.
To our knowledge, this is the first
standardized protocol for adjudication of
CLRD exacerbations. In population-based
and other large studies of CLRD risk,
administrative data are commonly used to
classify severe exacerbations, despite
ambiguities regarding the validity of this
approach (36). In the Copenhagen City
Heart Study, ICD-defined COPD-related
deaths showed evidence for both under-
and overdiagnosis compared with baseline
spirometry measures (15). In a study of
200 hospitalizations at two U.S. urban
academic medical centers, several ICD-
based algorithms used to classify COPD
exacerbations had very low sensitivity but
high specificity compared with physician-
report of COPD plus hospitalization for an
acute respiratory symptom (14). With
respect to asthma, the authors of a recent
Table 3. Interrater agreement for determination of chronic lower respiratory disease cases and exacerbations
Classified
Events
Agreement* Disagreement† k-Statistic 95% CI
Positive Negative
HCHS/SOL
Emergency department
CLRD cases 56 45 (80%) 9 (16%) 2 (4%) 0.88 0.71–1.00
CLRD exacerbations 56 41 (73%) 13 (23%) 2 (4%) 0.90 0.78–1.00
Hospitalizations
CLRD cases 61 47 (77%) 11 (18%) 3 (5%) 0.85 0.69–1.00
CLRD exacerbations 61 29 (48%) 27 (44%) 5 (8%) 0.84 0.70–0.97
MESA
Hospitalizations (ICD primary discharge diagnosis‡)
CLRD cases 99 94 (95%) 3 (3%) 2 (2%) 0.74 0.40–1.00
CLRD exacerbations 99 89 (90%) 3 (3%) 7 (7%) 0.42 0.07–0.78
Definition of abbreviations: CI = confidence interval; CLRD = chronic lower respiratory disease; HCHS/SOL = Hispanic Community Health Study/Study of
Latinos; ICD = International Classification of Diseases; MESA =Multi-Ethnic Study of Atherosclerosis.
Percentages are calculated out of the total number of eligible events of that type (emergency department visit or hospitalization) in that cohort.
*Positive agreement is defined as both reviewers confirming the event as at least a probable CLRD case or CLRD exacerbation; negative agreement is
defined as both reviewers determining that the event was not a CLRD case or CLRD exacerbation.
†Disagreement is defined as one reviewer classifying the event as at least a probable CLRD case or CLRD exacerbation and the other determining that it
was not consistent with a CLRD case or CLRD exacerbation.
‡All classified events in MESA had an ICD code for CLRD as the primary discharge diagnosis.
ORIGINAL RESEARCH
1062 AnnalsATS Volume 13 Number 7| July 2016
systematic review identified only three
studies reporting any validation metrics
for identification of bronchospasm, and
all three studies were in pediatric
populations (16).
Among events with CLRD as the
primary discharge diagnosis code, the
protocol confirmed almost all as CLRD
exacerbations. In HCHS/SOL, in which
events were ascertained by CLRD in any
ICD code position as well as by relevant
keywords, events without CLRD as the
primary discharge code were almost three
times as common as those with primary
coding; yet, only approximately one-half
and one-third were confirmed as probable
and highly probable or definite CLRD
exacerbations, respectively. These findings
support use of primary discharge
diagnosis codes as a relatively efficient
approach to capturing severe CLRD
exacerbations, although the broader
strategy used in HCHS/SOL more than
doubled the total number of confirmed
CLRD.
Findings were relatively consistent
across these two studies, even though
HCHS/SOL used prospective ascertainment
of CLRD events and its sample was
markedly younger, comprised exclusively of
Hispanic/Latino participants, and had more
asthma, whereas MESA collected CLRD
events retrospectively and its sample was
older, multiethnic, and had more COPD.
This between-cohort heterogeneity may be
seen as a limitation, especially for pooled
analyses. Nonetheless, the consistency of the
results suggests that the protocol is likely to
be applicable to other general population
studies as well as to disease-based studies
such as SPIROMICS (38), which is
collecting hospitalization records
using methodology similar to that of
HCHS/SOL.
Strengths and Limitations
Strengths of our study include systematic
application and evaluation of a protocol
HCHS/SOL EDHCHS/SOLHospitalization
Highly probable/definite
MESA Hospitalization
14 14 14
82 36 32
3 11 10
Number
Probable
Not confirmed
HCHS/SOL EDHCHS/SOLHospitalization
Highly probable/definite
MESA Hospitalization
72 21 33
23 10 10
4 30 13
Number
Probable
Not confirmed
CLRD Cases
HCHS/SOL ED
HCHS/SOL Hospitalization
MESA Hospitalization
0% 20% 40% 60% 80% 100%
CLRD Exacerbations
HCHS/SOL ED
HCHS/SOL Hospitalization
MESA Hospitalization
0% 20% 40% 60% 80% 100%
Figure 2. Confirmation of medical records as chronic lower respiratory disease (CLRD) cases and CLRD exacerbations, by cohort. ED = emergency
department; HCHS/SOL = Hispanic Community Health Study/Study of Latinos; MESA =Multi-Ethnic Study of Atherosclerosis.
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developed by CLRD experts in two
well-characterized, population-based
cohorts with standardized event follow-up,
strong minority representation, and
complementary age distributions. The
major limitation was the lack of a clear
gold standard for classifying CLRD
exacerbations. Although spirometry is the
current standard for diagnosis of COPD
and provides evidence of airflow limitation
(3), it is not recommended in the acute
setting and does not capture emphysema
or chronic bronchitis. Peak expiratory
flow rates were more commonly measured
during presumed asthma exacerbations,
in which context they have acceptable
diagnostic accuracy (4). Neither measure
was attempted systematically as part of
the study protocol; thus, data confirming
dynamic airflow limitation, which is a
quantitative physiologic correlate of COPD
and asthma exacerbations (4, 38), were
available in only a subset of events.
Nonetheless, the protocol made use of a
large amount of clinical data in an attempt
to provide an alloyed gold standard. The
prevalence of restriction on the basis of
spirometry was high in HCHS/SOL, which
may have been due to the high prevalence
of obesity or possible misclassification of
reference equations. Regardless of these
considerations, exclusion of persons with
restriction on the basis of spirometry did
not alter protocol performance.
Ascertainment of medical records was
limited to those coded with CLRD-related
ICD codes or keywords. We were therefore
unable to characterize the performance of
our protocol for events in which the
diagnosis of CLRDwas missed. Nonetheless,
the ascertainment criteria for CLRD
exacerbations in HCHS/SOL included
keywords for standard symptoms (cough)
and ICD codes for related diagnoses
(pulmonary heart failure, respiratory
failure). Also, the number of charts
evaluated was modest but sufficient to
demonstrate protocol feasibility and
favorable performance.
The protocol is appropriate only to
detect clinically significant CLRD cases and
“severe” CLRD exacerbations in persons
presenting for ED or hospital care.
Ascertainment of CLRD cases and CLRD
exacerbations in persons who do not
pursue or require this level of health care
use entails use of alternative methods.
The protocol is similar in this regard to
protocols used for heart failure (39) and
myocardial infarction (40), which do not
CLRD Cases
CLRD exacerbations
CLRD Exacerbations
CLRD Cases
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Absent (N=71)
Self-reported CLRD at study baseline
Present (N=145)
Percent confirmed
CLRD Cases
CLRD exacerbations
CLRD Exacerbations
CLRD Cases
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Absent (N=78)
Airflow limitation at study baseline
Present (N=69)
CLRD indicated as primary ICD-coded discharge diagnosis
CLRD Cases
CLRD exacerbations
CLRD Exacerbations
CLRD Cases
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Absent (N=84)
Present (N=132)
Not confirmed Probable Highly probable/Definite
Figure 3. Confirmation of chronic lower respiratory disease (CLRD) cases and CLRD exacerbations according to selected characteristics in the pooled
cohort sample. ICD = International Classification of Diseases.
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ascertain heart failure exacerbations treated
in the outpatient setting and “silent”
myocardial infarcts.
Conclusions
The protocol described in this article is
a practical and reliable approach to
defining CLRD cases and CLRD
exacerbations in epidemiologic studies,
in which valid measures of CLRD
endpoints are important for evaluating
primary and secondary prevention
strategies. Protocol-based classification
encompasses evolving definitions of CLRD
cases and confirms a substantial percentage
of CLRD cases in persons without
airflow limitation or self-reported CLRD.
CLRD exacerbations were confirmed in the
vast majority of records with a primary
discharge diagnosis of CLRD, compared
with only half of records with CLRD listed
as a nonprimary code. Our results justify
further examination of CLRD adjudication
in population-based cohorts, in other
cohorts collecting medical records
for at-risk smokers (e.g., SPIROMICS),
and potentially in electronic medical
records to promote large-scale CLRD
prevention research. n
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